Abstract:Peripheral pain signaling reflects a balance of pronociceptive and antinociceptive influences; the contribution by the gastrointestinal microbiota to this balance has received little attention. Disorders, such as inflammatory bowel disease and irritable bowel syndrome, are associated with exaggerated visceral nociceptive actions that may involve altered microbial signaling, particularly given the evidence for bacterial dysbiosis. Thus, we tested whether a community of commensal gastrointestinal bacteria derived from a healthy human donor (microbial ecosystem therapeutics; MET-1) can affect the excitability of male mouse DRG neurons. MET-1 reduced the excitability of DRG neurons by significantly increasing rheobase, decreasing responses to capsaicin (2 μm) and reducing action potential discharge from colonic afferent nerves. The increase in rheobase was accompanied by an increase in the amplitude of voltage-gated K+ currents. A mixture of bacterial protease inhibitors abrogated the effect of MET-1 effects on DRG neuron rheobase. A serine protease inhibitor but not inhibitors of cysteine proteases, acid proteases, metalloproteases, or aminopeptidases abolished the effects of MET-1. The serine protease cathepsin G recapitulated the effects of MET-1 on DRG neurons. Inhibition of protease-activated receptor-4 (PAR-4), but not PAR-2, blocked the effects of MET-1. Furthermore, Faecalibacterium prausnitzii recapitulated the effects of MET-1 on excitability of DRG neurons. We conclude that serine proteases derived from commensal bacteria can directly impact the excitability of DRG neurons, through PAR-4 activation. The ability of microbiota-neuronal interactions to modulate afferent signaling suggests that therapies that induce or correct microbial dysbiosis may impact visceral pain.SIGNIFICANCE STATEMENT Commercially available probiotics have the potential to modify visceral pain. Here we show that secretory products from gastrointestinal microbiota derived from a human donor signal to DRG neurons. Their secretory products contain serine proteases that suppress excitability via activation of protease-activated receptor-4. Moreover, from this community of commensal microbes, Faecalibacterium prausnitzii strain 16-6-I 40 fastidious anaerobe agar had the greatest effect. Our study suggests that therapies that induce or correct microbial dysbiosis may affect the excitability of primary afferent neurons, many of which are nociceptive. Furthermore, identification of the bacterial strains capable of suppressing sensory neuron excitability, and their mechanisms of action, may allow therapeutic relief for patients with gastrointestinal diseases associated with pain.

A network approach to investigating the key microbes and stability of gut microbial communities in a mouse neuropathic pain model

Gut Microbiota Influences Neuropathic Pain Through Modulating Proinflammatory and Anti-inflammatory T Cells

Integrated 16S rRNA Gene Sequencing and Metabolomics Analysis to Investigate the Important Role of Osthole on Gut Microbiota and Serum Metabolites in Neuropathic Pain Mice

Temporal Changes of Spinal Transcriptomic Profiles in Mice With Spinal Nerve Ligation.

Gut Microbiome and Plasma Metabolome Signatures in Middle-Aged Mice with Cognitive Dysfunction Induced by Chronic Neuropathic Pain

Gut microbiota depletion by antibiotics ameliorates somatic neuropathic pain induced by nerve injury, chemotherapy, and diabetes in mice

Short-chain fatty acids contribute to neuropathic pain via regulating microglia activation and polarization

Integration of microbiota and metabolomics reveals the analgesic mechanisms of emodin against neuropathic pain

Protease-Mediated Suppression of DRG Neuron Excitability by Commensal Bacteria

Synergic Effect of Early Administration of Probiotics and Adipose-Derived Mesenchymal Stem Cells on Alleviating Inflammation-Induced Chronic Neuropathic Pain in Rodents

Key Role of Gut Microbiota in Anhedonia-Like Phenotype in Rodents with Neuropathic Pain.

microRNA-Based Network and Pathway Analysis for Neuropathic Pain in Rodent Models

Gut microbiota regulates neuropathic pain: potential mechanisms and therapeutic strategy

Gut Microbiota and Their Metabolite Profiles Following Peripheral Nerve Xenotransplantation

The gut microbiome modulates nitroglycerin-induced migraine-related hyperalgesia in mice

Immune cells mediate the effects of gut microbiota on neuropathic pain: a Mendelian randomization study

Pivotal Role of the Gut Microbiota in Congenital Insensitivity to Pain with Anhidrosis

Pain Regulation by Gut Microbiota: Molecular Mechanisms and Therapeutic Potential

The Causal Connections Between Gut Microbiota and Chronic Pain and Pain Phenotypes Through the Gut-Brain Axis: A Mendelian Randomization Study and Mediation Analysis

Proteomic and Phosphoproteomic Changes of MAPK-Related Inflammatory Response in an Animal Model of Neuropathic Pain by Differential Target Multiplexed SCS and Low-Rate SCS

Microglia and Monocytes Synergistically Promote the Transition from Acute to Chronic Pain after Nerve Injury